top of page

Stage 1

Stage 2

Stage 3

Stage 4

ANM02

Untitled(1)awdawd_edited.jpg

  • Stage 1 - Discovery and candidate selection

  • Stage 2 -Lead optimization and pilot effectiveness

  • Stage 3 -Target animal safety and dose selection

  • Stage 4 -Pivotal field effectiveness studies

ANM02 is a 90-day injectable phenylpropanolamine (PPA) drug candidate for the treatment of canine urinary incontinence. ANM02 is designed to provide sustained symptom control with a single injection, reducing the burden of frequent dosing while improving treatment adherence and quality of life for pets and their owners.

bottom of page